Short Term Trading Weekend Lounge: 7 -9 Apr, page-153

STTCOMP AHZ, FA Long

biotech - products for cardiovascular repair, medical supplies and immunotherapy division

MC 75ish mill SP 33cents

I am resubmitting this tip as the share price hasnt really moved but its gouing to break its trading range within the month, ill take a punt on which way. main reason being Vax results are due, collaboration with big pharma to be named (hopefully within tip timeframe), quarterly should be strong and FDA approval sought for their new product which should be fast since they already have products approved. 60% share price move on last fda approval announcement.they also applied for international patents on their gene sequence which wouldnt be happening if it was a failure i believe (speculating). also court case was settled last quarter.

heres my previous tip and all still stands:

world class products in cardiovascular regeneration which is steadily gaining traction with massive quarter on quarter sustained growth and a possible cure for herpes with unblinded interim phase 2 results due oct-dec this year (i expect these to be late)
have a few other vaccines in the pipeline, HPV, another cervical cancer one i think.
in charge of the immunotherapies division (the vaccines) is world class PR Ian Frazer, the only person to have ever come up with a vaccine for cancer (gardasil, cervical cancer)
on top of these 2 potential blue sky drivers they have a profitable infusion pump business which appears is the only thing that has kept the ship afloat over the last few years.
Old management were absolutely woeful and ran this into the ground with CR after CR, poor shareholder communication etc, leaving the shareprice where it is now which is why i believe it has a lot of room to move back upwards.
it had a high of up near $1.82 about 3 years ago and has been in a steady downward decline ever since.
broke out of downward trend which coincided with old board getting the boot and wayne coming into clean things up.
so all new management with new CEO wayne paterson who really seems to have turned things around if he delivers on promises.
cut expenses massively got rid of around 30% of workforce and has provided a path to profitability much quicker than expected under old management.
I expect ALOT of buying pressure coming up to the release of the unblided HSV2 reults towards the end of the year, given that its a 6 billion dollar market which could potentially be tapped into.
Once cardiocel is profitable and IF professor Frazer can nail it again, this thing will be an absolute monster. please note the IF